Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CD | O00329 | 12/20 | 0.59 |
| ▸ | PIK3CG | P48736 | 8/20 | 0.56 |
| ▸ | PIK3CA | P42336 | 4/20 | 0.54 |
| ▸ | PIK3CB | P42338 | 4/20 | 0.54 |
| ▸ | ABL1 | P00519 | 1/20 | 0.54 |
| ▸ | SRC | P12931 | 1/20 | 0.54 |
| ▸ | MTOR | P42345 | 1/20 | 0.54 |
| ▸ | PRKDC | P78527 | 1/20 | 0.54 |
| ▸ | PIK3C2B | O00750 | 4/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9924629 | 0.93 | PIK3CD (0.68) | PIK3CDPIK3CGPIK3CAPIK3CBABL1 | |
| SCHEMBL9924634 | 0.89 | PIK3CG (0.63) | PIK3CDPIK3CGPIK3CAPIK3CBABL1 | |
| SCHEMBL9884210 | 0.87 | PIK3CD (0.68) | PIK3CDPIK3CGPIK3CAPIK3CBABL1 | |
| SCHEMBL9884115 | 0.85 | PIK3CD (0.73) | PIK3CDPIK3CGPIK3CAPIK3CBABL1 | |
| SCHEMBL18708609 | 0.84 | PIK3CD (0.64) | PIK3CDPIK3CGPIK3CAPIK3CBABL1 | |
| SCHEMBL9884116 | 0.84 | PIK3CD (0.64) | PIK3CDPIK3CGPIK3CAPIK3CBABL1 | |
| SCHEMBL9884123 | 0.84 | PIK3CD (0.68) | PIK3CDPIK3CGPIK3CAPIK3CBABL1 | |
| SCHEMBL20725920 | 0.84 | PIK3CD (0.74) | PIK3CDPIK3CGPIK3CAPIK3CBABL1 | |
| SCHEMBL18708811 | 0.82 | PIK3CD (0.62) | PIK3CDPIK3CGPIK3CAPIK3CBABL1 | |
| SCHEMBL9884234 | 0.82 | PIK3CD (0.63) | PIK3CDPIK3CGPIK3CAPIK3CBABL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160113932-A1 | TREATMENT OF CANCERS USING PI3 KINASE ISOFORM MODULATORS | INFINITY PHARMACEUTICALS, INC. (US) | 2016-04-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160113932-A1 | TREATMENT OF CANCERS USING PI3 KINASE ISOFORM MODULATORS | PIK3CA, PIK3CG, PIK3CD | PIK3CD 3/4885PIK3CG 2/4885PIK3CA 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.